Intradiscal Delivery of Notoginsenoside R1‐Loaded PLGA Nanoparticles Attenuates Intervertebral Disc Degeneration in Rats
Journal of Cellular and Molecular Medicine · 2026
DOI: 10.1111/jcmm.71378 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2026. Verfasst von Baichuan Zheng und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, Guangdong, China. Hauptthemen laut MEDLINE: Polylactic Acid-Polyglycolic Acid Copolymer, Ginsenosides, Nanoparticles, Intervertebral Disc Degeneration. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangdong Basic and Applied Basic Research Foundation, Traditional Chinese Medicine Bureau of Guangdong Province, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Intervertebral disc degeneration (IVDD) contributes to persistent low back pain, but existing treatments focus on symptom relief rather than addressing the degeneration. Notoginsenoside R1 (NR1), a bioactive saponin derived from Panax notoginseng, has exhibited protective effects in experimental models of disc injury. However, its clinical application is limited by poor bioavailability and rapid clearance. Here, NR1 was encapsulated into poly(lactic‐co‐glycolic acid) nanoparticles (NR1@PLGA) to improve local drug retention. NR1@PLGA showed uniform particle characteristics, prolonged NR1 release, and time‐dependent uptake by nucleus pulposus cells (NPCs). Under H 2 O 2 ‐induced oxidative stress, NR1@PLGA reduced SA‐β‐gal‐positive cells, preserved aggrecan and collagen II (Col‐2) expression, and improved cell viability compared with free NR1 at the same concentration. In a rat caudal puncture model, intradiscal administration of NR1@PLGA preserved T2‐weighted MRI signals, improved histological outcomes, increased aggrecan expression, and decreased MMP‐13 levels. No obvious abnormalities were observed in major organs or serum biochemical indicators related to liver and kidney function during the 4‐week observation period. These results demonstrate that NR1@PLGA is a potential treatment for IVDD, with PLGA encapsulation enhancing the efficacy of NR1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, Guangdong, China.
- Guangdong Medical University, Zhanjiang, Guangdong, China.
- The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, Guangdong, China.
- Shenzhen School of Clinical Medicine, Southern Medical University, Shenzhen, China.
- Dongguan Key Laboratory of Basic, Clinical and Digital Research on Common Orthopedic Diseases, Dongguan, Guangdong, China.
ORCID-Profile: Songbo Li
Förderung
- Guangdong Basic and Applied Basic Research Foundation
- Traditional Chinese Medicine Bureau of Guangdong Province
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Zheng, B., Zhong, H., Wang, Z., Qin, J., Xie, Z., Tang, R., Hu, C., Zhang, X., Li, J., & Li, S. (2026). Intradiscal Delivery of Notoginsenoside R1‐Loaded PLGA Nanoparticles Attenuates Intervertebral Disc Degeneration in Rats. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.71378
Vancouver
Zheng B, Zhong H, Wang Z, Qin J, Xie Z, Tang R, et al. Intradiscal Delivery of Notoginsenoside R1‐Loaded PLGA Nanoparticles Attenuates Intervertebral Disc Degeneration in Rats. Journal of Cellular and Molecular Medicine. 2026. doi:10.1111/jcmm.71378
BibTeX
@article{Zheng2026,
author = {Zheng, Baichuan and Zhong, Haotian and Wang, Zhengwei and Qin, Junyu and Xie, Ziying and Tang, Rong and Hu, Chengshang and Zhang, Xiuming and Li, Jianwen and Li, Songbo},
title = {Intradiscal Delivery of Notoginsenoside R1‐Loaded PLGA Nanoparticles Attenuates Intervertebral Disc Degeneration in Rats},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
doi = {10.1111/jcmm.71378}
}
EUVIMED